NutNow you can listen to the Fox News items!
The Trump administration has expressed interest in exploring psychedelic for their potential for PTSD treatment and other weakening mental health problems, several officials have shared.
“The Department shares the goal of ensuring that all North -Americans, especially the veterans of our nation, have access to safe and effective treatments for conditions such as PTSD, addiction and depression,” spokesman for the United States Health and Human Services Department (HHS), directed by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital.
“Secretary Kennedy is committed to applying rigorous and evidence based on research efforts to meet these serious health challenges.”
The FDA approves the first AI tool to predict the risk of breast cancer
In recent years, researchers have been actively investigating the potential of psychedelic, such as MDMA and Psilocybin (“Magic Mushrooms”) to treat mental health disorders.
The MDMA is not approved for clinical use by the United States Food and Drug Administration (FDA), but can be studied in clinical environments.
Psychedelics Research has obtained the support of the Trump administration to treat the PTSD and mental health conditions. (Istock)
The psilocybin appears as a substance in the list and by virtue of the law of controlled substances, which means that it has “a high potential of abuse, [is not] Currently accepted for medical use in treatment in the United States and [has] Lack of security accepted for use under medical supervision. ”
The therapy assisted by the psilocibine, however, is legal to Oregon, Colorado and New Mexico.
“Show Promise”
Psychedelic medications are “showing a real promise,” according to Dr. Luke Twelves, a medical doctor and Vice President of Medical for Lindus Health in London.
According to the Twist, clinical trials have found these safe and effective treatments for patients fighting serious mental health problems.
Common supplements and medicines could cause liver damage, according to studies
“Take the psilocybin, for example, are demonstrating remarkable results for severe depression that has not responded to other medicines,” Fox News Digital told. “MDMA shows similar advances for PTSD treatment.”
Clinical trials are also investigating how psychedelic can help end -of -life anxiety, addiction, eating disorders, chronic pain and touch, he added.
In recent years, researchers have been actively investigating the potential of psychedelic, such as MDMA and PSILOCIBIN to treat mental health disorders. (Istock)
The researchers have faced challenges in terms of appropriate regulatory obstacles and controls, tweets said.
“Given that these treatments could be transformed [the] Life of people suffering from conditions in which nothing else has worked effectively, it is crucial that we complete this research correctly, “he said.” The goal is to bring safe psychedelic therapies to patients who need them most. “
Potential for veterans
At the Cabinet meeting of May 1, President Trump, Secretary of the Department of Veterans Affairs Doug Collins, said that “we are opening the possibility of psychedelic treatment”.
Retired army sergeant Jonathan Lubecki recently told Fox News’ Alexandria Hoff that MDMA stopped his PTSD while participating in a clinical trial.
It is now open to the possibility of psychedelic treatment to promote the health of veterans. (Istock)
“”[I] I took my first dose of MDMA. I have only taken it three times as part of the clinical trial, I have not taken it since then and I have not found the need to take it since then, because I have not had PTSD, “he said.
Peter Kasperowicz, a press secretary of the veterans department, told Fox News Digital that the department is safely exploring all the ways that promote the health of veterans.
Fallujah Vet turns the Heroism Medal into a healing mission for warriors with the service dog program
“Preliminary findings have produced positive results in psychedelic -assisted therapies to deal with mental health conditions,” he said.
Currently, the VA is conducting 11 clinical trials in several phases, with a total of 800 veterans planned.
Click here to get the Fox News app
“The purpose of these trials is to determine if compounds such as MDMA and psilocibine can treat veterans with post -traumatic stress disorder, treatment -resistant depressive disorder, major depressive disorder and possibly other mental health conditions,” said Kasperowicz.
The psilocibine is a medicine of the list and by virtue of the law of controlled substances, but the therapy assisted by the PSILOCIBIN is legal in Oregon, Colorado and New Mexico. (Istock)
An MDMA study published in the January 2025 number of the American Journal of Psychiatry found that the substance is “unlike classical psychedelic”.
The study stated that “MDMA allows the individual to maintain an intact ego functioning and a greater degree of cognitive and perceptual lucidity, although he experiences a state of consciousness that is prostocial that facilitates deeply emotional therapeutic advances.”
Click here to register -you are in our health newsletter
The researchers concluded that MDMA showed “improved levels of trust, empathy, self -compathy and a” tolerance window “that lacks traditional psychotherapy.
Currently, it has 11 psychedelic clinical trials in various phases. (Istock)
Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that “now is the time to address the mental health crisis”.
He said it is “rewarding” that administration officials value the potential benefits of seeking alternative mental health treatments.
“The moment is now to address the mental health crisis.”
Cybin is currently in phase 3 of a CYB003 study, a type of psilocybin that has received an innovative designation of FDA as an additional treatment for major depressive disorder (MDD).
“In the study of Cybin phase 2, long -term efficiency results showed that 71% of participants were remissioned by depression and 100% of participants responded to treatment at 12 months after only two doses of 16 mg of CYB003,” Drysdale said.
Risks and precautions
Dr. Marc Siegel, Clinical Professor of Medicine of NYU Langone Medical Center and Principal Medical Analyst of Fox News, previously interviewed two of the country’s leading researchers on psychedelic: Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma of Mt. Sinai in New York, and Dr. Charles Marmar, Director of the PTSD Research Program by Nyu Langone.
“There is a great disadvantage in terms of non -regulated recreational uses.”
“They agree that there is a therapeutic potential if carefully studied under a very strict medical orientation, but there is a great disadvantage in terms of non -regulated recreational uses,” said Siegel in Fox News Digital at that time.
Experts emphasize the importance of administering psychedelic in a safe environment when dealing with mental health conditions. (Istock)
“The two doctors see a probable therapeutic value for psychedelic if they carefully manage medical experts,” Siegel added.
Ryan Moss, Health Filament Science Chief, a natural psychedelic medicine development company in the Clinical Phase in Canada, emphasized that it is important to administer psychedelic in a safe environment when dealing with mental health conditions.
For more health items, visit www.foxnews.com/health
“Psychedelic experiences can sometimes have anxiety, hallucinations and paranoia,” Moss in Fox News Digital told. “Some patients who use traditional psychedelic have reported by experiencing adverse cardiovascular events during clinical trials.”
To mitigate these risks, Moss recommended that participants in clinical trials be prepared and exhaustive by professionals trained during the sessions.
Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed to reporting.
#Psychedelic #potential #mental #health #treatment #explored #Trump #administration
Image Source : www.foxnews.com